Published in Am J Kidney Dis on December 05, 2012
Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clin J Am Soc Nephrol (2013) 1.11
Dabigatran pharmacokinetics--implications for treatment. Am J Kidney Dis (2013) 1.07
Dabigatran and kidney disease: a bad combination. Clin J Am Soc Nephrol (2013) 0.95
New oral anticoagulants for atrial fibrillation: are they worth the risk? P T (2014) 0.87
Translational insights into traumatic brain injury occurring during dabigatran or warfarin anticoagulation. J Cereb Blood Flow Metab (2014) 0.83
New oral anticoagulants and the cancer patient. Oncologist (2013) 0.83
Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. Circulation (2017) 0.82
Coagulopathy and Extremely Elevated PT/INR after Dabigatran Etexilate Use in a Patient with End-Stage Renal Disease. Case Rep Med (2013) 0.80
Interrupting anticoagulation in patients with nonvalvular atrial fibrillation. P T (2014) 0.80
Use of 4-factor prothrombin complex concentrate in the treatment of a gastrointestinal hemorrhage complicated by dabigatran. Int J Emerg Med (2015) 0.80
Characteristics of Symptomatic Intracranial Hemorrhage in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulant Therapy. PLoS One (2015) 0.79
Bilateral Spontaneous Hyphema, Vitreous Hemorrhage, and Choroidal Detachment With Concurrent Dabigatran Etexilate Therapy. Ophthalmic Surg Lasers Imaging Retina (2016) 0.79
Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran. Vasc Health Risk Manag (2015) 0.78
Enhanced elimination of dabigatran through extracorporeal methods. J Med Toxicol (2015) 0.76
Dabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional Experience. Neurohospitalist (2015) 0.75
Dabigatran: patient management in specific clinical settings. Wien Klin Wochenschr (2014) 0.75
Management of gastrointestinal bleeding in patients anticoagulated with dabigatran compared with warfarin: a retrospective, comparative case review. Cardiovasc Diagn Ther (2014) 0.75
Traumatic fatal cerebral hemorrhage in an old patient with a history of multiple sclerosis under dabigatran: a case report and review of the literature. J Geriatr Cardiol (2015) 0.75
In reply to 'Dabigatran pharmacokinetics--implications for treatment'. Am J Kidney Dis (2013) 0.75
Dabigatran excess: case report and review of the literature. Cardiol Ther (2013) 0.75
Dabigatran etixilate and traumatic brain injury: Evolving anticoagulants require evolving care plans. World J Clin Cases (2014) 0.75
Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit. Clin Kidney J (2015) 0.75
Use of Continuous Renal Replacement Therapy for Removal of Dabigatran in a Patient in Need of Emergent Surgery. Case Rep Crit Care (2016) 0.75
Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation. Am J Cardiovasc Drugs (2015) 0.75
Use of hemodialysis for the treatment of intracerebral hemorrhage in patients on dabigatran with normal renal function. Clin Nephrol Case Stud (2014) 0.75
Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery. Am J Health Syst Pharm (2009) 1.60
Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother (2009) 1.25
Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy (2009) 1.24
Racial and gender differences in the incidence of recurrent venous thromboembolism. Thromb Haemost (2006) 1.04
Outcomes of upper arm arteriovenous fistulas for maintenance hemodialysis access. Arch Surg (2004) 1.01
Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values. Am J Clin Pathol (2004) 0.92
Upper arm arteriovenous fistula versus forearm looped arteriovenous graft for hemodialysis access: a comparative analysis. Ann Vasc Surg (2005) 0.91
Usefulness of optical density values from heparin-platelet factor 4 antibody testing and probability scoring models to diagnose heparin-induced thrombocytopenia. Am J Clin Pathol (2007) 0.91
Rivaroxaban: practical considerations for ensuring safety and efficacy. Pharmacotherapy (2013) 0.90
Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing. Ann Pharmacother (2004) 0.88
Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay. Ann Pharmacother (2013) 0.87
Drug-induced thrombocytopenia in critically ill patients. Crit Care Med (2010) 0.86
Critical pathways: the role of pharmacy today and tomorrow. Pharmacotherapy (2006) 0.85
Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness. Pharmacotherapy (2011) 0.85
The need for PGY2-trained clinical pharmacy specialists. Pharmacotherapy (2014) 0.85
Management of bleeding and reversal strategies for oral anticoagulants: clinical practice considerations. Am J Health Syst Pharm (2013) 0.84
Vitamin K dosing to reverse warfarin based on INR, route of administration, and home warfarin dose in the acute/critical care setting. Ann Pharmacother (2012) 0.82
The efficacy of factor VIIa in emergency department patients with warfarin use and traumatic intracranial hemorrhage. Acad Emerg Med (2010) 0.82
Bivalirudin in pediatric patients maintained on extracorporeal life support. Pediatr Crit Care Med (2013) 0.80
Key articles and guidelines in the treatment of venous thromboembolism. Pharmacotherapy (2009) 0.79
Key articles and guidelines for the prevention of venous thromboembolism. Pharmacotherapy (2009) 0.79
Key articles and guidelines relative to intensive care unit pharmacotherapy: 2009 update. Pharmacotherapy (2009) 0.78
Considerations for drug dosing post coronary artery bypass graft surgery. Ann Pharmacother (2008) 0.77
Variability of plasma anti-Xa activities with different lots of enoxaparin. Ann Pharmacother (2004) 0.77
Systemic anticoagulant prophylaxis for central catheter-associated venous thrombosis in cancer patients. Ann Pharmacother (2007) 0.76
Initiating warfarin therapy. Ann Pharmacother (2003) 0.75
Achieving optimal antiarrhythmic therapy in advanced cardiac life support. Crit Care Med (2006) 0.75
In reply to 'Dabigatran pharmacokinetics--implications for treatment'. Am J Kidney Dis (2013) 0.75
Filtering out important considerations for developing drug-dosing regimens in extended daily dialysis. Crit Care Med (2006) 0.75
Uncertain times for oral anticoagulation therapy. Am J Health Syst Pharm (2005) 0.75
Safety of new oral anticoagulants with dual antiplatelet therapy in patients with acute coronary syndromes. Ann Pharmacother (2013) 0.75
Ideal cardiovascular health and progression of CKD: perhaps not so "simple". J Am Soc Nephrol (2013) 0.75
Aminoglycoside elimination in extended duration hemodialysis. Ann Pharmacother (2006) 0.75
Clinical experience with aminoglycosides in dialysis-dependent patients: risk factors for mortality and reassessment of current dosing practices. Ann Pharmacother (2011) 0.75
Comparison of bivalirudin dosing strategies using total, adjusted, and ideal body weights in obese patients with heparin-induced thrombocytopenia. Pharmacotherapy (2012) 0.75
Key articles and guidelines relative to treatment of patients with acute coronary syndromes. Pharmacotherapy (2004) 0.75
Clinical and management challenges in preventing venous thromboembolism in health systems: a case-based panel discussion. Am J Health Syst Pharm (2010) 0.75
Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach. Ann Pharmacother (2006) 0.75
Transitioning from traditional to novel anticoagulants: the impact of oral direct thrombin inhibitors on anticoagulation management. Pharmacotherapy (2004) 0.75
Warfarin initiation and monitoring with clotting factors II, VII, and X. Ann Pharmacother (2003) 0.75
Filtering Out Use of DOACs in Hemodialysis. Ann Pharmacother (2017) 0.75
Inventory control for advanced cardiac life support medications. Ann Pharmacother (2002) 0.75
Key articles and guidelines in the management of acute coronary syndromes and in percutaneous coronary intervention: 2007 update. Pharmacotherapy (2007) 0.75
Bivalirudin for anticoagulation during hypothermic cardiopulmonary bypass and recombinant factor VIIa for iatrogenic coagulopathy. Ann Pharmacother (2011) 0.75
Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia. Ann Pharmacother (2011) 0.75
Phenytoin assay errors in uremia. Ann Pharmacother (2002) 0.75